Rameda notified of Anviziram, Remdesivir-Rameda vial prices by Egyptian Drug Authority, on track to market first Remdesivir-Rameda production in September 2020
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents SAE (Rameda), RMDA.CA on the EGX, a leading Egyptian pharmaceutical company, announced today that it has been notified by the Egyptian Drug Authority of the public price for its product “Anviziram.” Anviziram, which contains the active pharmaceutical ingredient Favipiravir will be sold for EGP 1,260 per each 40-tablet pack. Rameda has also been notified by the Egyptian Drug Authority of the public price for intravenous “Remdesivir” powder vials for use in the treatment of patients suffering from covid-19. The drug will be sold at a price of EGP 680 per vial under the brand name Remdesivir-Rameda (Lyophilized powder for IV Solution Infusion).
Rameda had received approval from the Egyptian Drug Authority to begin manufacturing RemdisivirRameda in June and confirms that it is on track to bring its first production to market in September 2020. Remdesivir is a broad-spectrum antiviral medication which has been used in treatment of critical covid19 cases. Rameda will be the first company to produce “Remdesivir” powder in vial form which can be stored at room temperature.